Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Investing.com -- Glenmark Pharmaceuticals (NSE:GLEN) Inc., USA has launched the Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), a product that is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005% from Upjohn US 2 LLC.
The Xalatan Ophthalmic Solution, 0.005% market achieved annual sales of approximately $113.5 million, according to IQVIA sales data for the 12-month period that ended in December 2024.
The Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is the fourth ophthalmic product launched by Glenmark. Marc Kikuchi, President & Business Head, North America at Glenmark, expressed enthusiasm about the launch, stating that the new addition underscores the company's commitment to meeting market needs and providing quality solutions for customers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.